Phibro Animal Health Corporation experienced substantial growth in the three months ended December 31, 2024, with net sales increasing by 24% to $309.3 million and net income rising by 50% to $3.185 million. This growth was largely driven by the acquisition of Zoetis's medicated feed additive portfolio and increased demand across its Animal Health segment.
Net sales increased by 24% to $309.3 million for the three months ended December 31, 2024, compared to the same period last year.
Net income grew by 50% to $3.185 million, up from $1.274 million in the prior year period.
The Animal Health segment saw a 33% increase in net sales, primarily due to the acquisition of Zoetis's MFA portfolio.
Gross profit improved by 30% to $101.9 million, with the gross margin increasing to 32.9% of net sales.
The company's forward guidance is not explicitly stated in a consolidated section, but various factors influencing future performance are discussed, including ongoing conflicts, regulatory developments, and macroeconomic conditions.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance